Sunday, April 28, 2024
ADVT 
Health

FDA calls for removal of fruity, disposable Puff Bar vapes

Darpan News Desk The Canadian Press, 20 Jul, 2020 06:14 PM
  • FDA calls for removal of fruity, disposable Puff Bar vapes

U.S. health officials are cracking down on a brand of fruity disposable e-cigarettes that is popular with teenagers, saying the company never received permission to sell them in the U.S.

The Food and Drug Administration sent a letter Monday telling the company to remove Puff Bar e-cigarettes from the market within 15 business days, including flavours like mango, pink lemonade and strawberry. The agency sent warning letters to nine other companies either selling similarly unauthorized e-cigarettes or nicotine solutions that illegally appeal to children. Some of those mimic packaging of sweets and cereals like Twinkies and Cinnamon Toast Crunch.

The regulatory action comes months after anti-vaping advocates warned that disposable vapes like Puff Bar were a glaring loophole in the FDA's ban on flavoured e-cigarettes. That policy, which took effect in February, narrowly targeted reusable vaping devices like Juul, the blockbuster brand that helped trigger the teen vaping craze in the U.S. Under the policy, only menthol and tobacco flavours were allowed for those devices. But the flavour restrictions did not apply to disposable vaping products like Puff Bar.

The seller of Puff Bar, Cool Clouds Distribution of Glendale, California, did not immediately respond to emailed messages seeking comment Monday afternoon.

Anti-vaping groups had petitioned the company to remove all disposable vaping products from market, warning they have caught on with teenagers who previously used discontinued Juul flavours like mint and mango.

For months, the FDA has been consumed with the coronavirus outbreak, reviewing new tests and treatments. Earlier this year, the agency suspended in-person inspections at vape shops and convenience stores aimed at enforcing sales restrictions. Late last year, the U.S. raised the legal age to purchase e-cigarettes and all other tobacco and vaping products from 18 to 21.

___

MORE Health ARTICLES

Health panel may open lung cancer screening to more smokers

Health panel may open lung cancer screening to more smokers
A U.S. health panel wants to widen the number of Americans offered yearly scans for lung cancer by opening the screening to less-heavy smokers.

Health panel may open lung cancer screening to more smokers

Health care workers at risk of PTSD from COVID: guide

Health care workers at risk of PTSD from COVID: guide
The Centre of Excellence on Post-Traumatic Stress Disorder says health-care workers on the front lines of the COVID-19 pandemic are susceptible to severe stress that could cause long-term psychological damage.

Health care workers at risk of PTSD from COVID: guide

Doctors say experimental treatment may have rid man of HIV

Doctors say experimental treatment may have rid man of HIV
A Brazilian man infected with the AIDS virus has shown no sign of it for more than a year since he stopped HIV medicines after an intense experimental drug therapy aimed at purging hidden, dormant virus from his body, doctors reported Tuesday.

Doctors say experimental treatment may have rid man of HIV

AIDS report: Kids are lagging and COVID-19 is harming care

AIDS report: Kids are lagging and COVID-19 is harming care
New numbers on the global AIDS epidemic show some big successes, such as fewer deaths and new infections. But there are also some tragic failures: Only half the children with HIV, the virus that causes the disease, are getting treatment.

AIDS report: Kids are lagging and COVID-19 is harming care

Dr.Bal Pawa shares information on how to tackle mental health challenges amidst COVID-19

Dr.Bal Pawa shares information on how to tackle mental health challenges amidst COVID-19
Dr. Bal Pawa is a uniquely qualified pharmacist and medical doctor. The combined knowledge, plus 3 decades of clinical experience have fuelled her passion to change the way medical care is delivered

Dr.Bal Pawa shares information on how to tackle mental health challenges amidst COVID-19

Gilead's $2,340 price for coronavirus drug draws criticism

Gilead's $2,340 price for coronavirus drug draws criticism
The maker of a drug shown to shorten recovery time for severely ill COVID-19 patients says it will charge $2,340 for a typical treatment course for people covered by government health programs in the United States and other developed countries.

Gilead's $2,340 price for coronavirus drug draws criticism